These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27082864)

  • 21. Brain serotonin transporter occupancy by oral sibutramine dosed to steady state: a PET study using (11)C-DASB in healthy humans.
    Talbot PS; Bradley S; Clarke CP; Babalola KO; Philipp AW; Brown G; McMahon AW; Matthews JC
    Neuropsychopharmacology; 2010 Feb; 35(3):741-51. PubMed ID: 19890256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypobaric hypoxia exposure in rats differentially alters antidepressant efficacy of the selective serotonin reuptake inhibitors fluoxetine, paroxetine, escitalopram and sertraline.
    Kanekar S; Sheth CS; Ombach HJ; Olson PR; Bogdanova OV; Petersen M; Renshaw CE; Sung YH; D'Anci KE; Renshaw PF
    Pharmacol Biochem Behav; 2018 Jul; 170():25-35. PubMed ID: 29738811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modeling the acute pharmacological response to selective serotonin reuptake inhibitors in human brain using simultaneous PET/MR imaging.
    Gryglewski G; Klöbl M; Berroterán-Infante N; Rischka L; Balber T; Vanicek T; Pichler V; Kautzky A; Klebermass EM; Reed MB; Vraka C; Hienert M; James GM; Silberbauer L; Godbersen GM; Unterholzner J; Michenthaler P; Hartenbach M; Winkler-Pjrek E; Wadsak W; Mitterhauser M; Hahn A; Hacker M; Kasper S; Lanzenberger R
    Eur Neuropsychopharmacol; 2019 Jun; 29(6):711-719. PubMed ID: 31076187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A dose-finding study of duloxetine based on serotonin transporter occupancy.
    Takano A; Suzuki K; Kosaka J; Ota M; Nozaki S; Ikoma Y; Tanada S; Suhara T
    Psychopharmacology (Berl); 2006 Apr; 185(3):395-9. PubMed ID: 16506079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 5-HTT and 5-HT(1A) receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects.
    Stenkrona P; Halldin C; Lundberg J
    Eur Neuropsychopharmacol; 2013 Oct; 23(10):1190-8. PubMed ID: 23428337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diencephalic serotonin transporter availability predicts both transporter occupancy and treatment response to sertraline in obsessive-compulsive checkers.
    Zitterl W; Stompe T; Aigner M; Zitterl-Eglseer K; Ritter K; Zettinig G; Hornik K; Asenbaum S; Pirker W; Thau K
    Biol Psychiatry; 2009 Dec; 66(12):1115-22. PubMed ID: 19717141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serotonin transporter occupancy by the SSRI citalopram predicts default-mode network connectivity.
    Schrantee A; Lucassen PJ; Booij J; Reneman L
    Eur Neuropsychopharmacol; 2018 Oct; 28(10):1173-1179. PubMed ID: 30082141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors.
    Chen F; Larsen MB; Sánchez C; Wiborg O
    Eur Neuropsychopharmacol; 2005 Mar; 15(2):193-8. PubMed ID: 15695064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography.
    Comley RA; Salinas CA; Slifstein M; Petrone M; Marzano C; Bennacef I; Shotbolt P; Van der Aart J; Neve M; Iavarone L; Gomeni R; Laruelle M; Gray FA; Gunn RN; Rabiner EA
    J Pharmacol Exp Ther; 2013 Aug; 346(2):311-7. PubMed ID: 23685546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Misunderstandings about how to choose a reference region.
    Meyer JH; Wilson AA; Ginovart N; Houle S
    Biol Psychiatry; 2007 Jun; 61(11):1314; author reply 1314-5. PubMed ID: 16989780
    [No Abstract]   [Full Text] [Related]  

  • 31. PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopram.
    Lundberg J; Christophersen JS; Petersen KB; Loft H; Halldin C; Farde L
    Int J Neuropsychopharmacol; 2007 Dec; 10(6):777-85. PubMed ID: 17201996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Occupancy of the serotonin transporter by fluoxetine, paroxetine, and sertraline: in vivo studies with [125I]RTI-55.
    Scheffel U; Kim S; Cline EJ; Kuhar MJ
    Synapse; 1994 Apr; 16(4):263-8. PubMed ID: 8059336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503.
    Ishikawa M; Ishiwata K; Ishii K; Kimura Y; Sakata M; Naganawa M; Oda K; Miyatake R; Fujisaki M; Shimizu E; Shirayama Y; Iyo M; Hashimoto K
    Biol Psychiatry; 2007 Oct; 62(8):878-83. PubMed ID: 17662961
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utility of small-animal positron emission tomographic imaging of rats for preclinical development of drugs acting on the serotonin transporter.
    Saijo T; Maeda J; Okauchi T; Maeda J; Morio Y; Kuwahara Y; Suzuki M; Goto N; Suzuki K; Higuchi M; Suhara T
    Int J Neuropsychopharmacol; 2009 Sep; 12(8):1021-32. PubMed ID: 19236731
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serotonin transporter occupancy with TCAs and SSRIs: a PET study in patients with major depressive disorder.
    Lundberg J; Tiger M; Landén M; Halldin C; Farde L
    Int J Neuropsychopharmacol; 2012 Sep; 15(8):1167-72. PubMed ID: 22243688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of sertraline, paroxetine, fluoxetine and escitalopram on testicular tissue and oxidative stress parameters in rats.
    Erdemir F; Atilgan D; Firat F; Markoc F; Parlaktas BS; Sogut E
    Int Braz J Urol; 2014; 40(1):100-8. PubMed ID: 24642156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study.
    Meyer JH; Wilson AA; Ginovart N; Goulding V; Hussey D; Hood K; Houle S
    Am J Psychiatry; 2001 Nov; 158(11):1843-9. PubMed ID: 11691690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of clinical response based on pharmacokinetic/pharmacodynamic models of 5-hydroxytryptamine reuptake inhibitors in mice.
    Kreilgaard M; Smith DG; Brennum LT; Sánchez C
    Br J Pharmacol; 2008 Sep; 155(2):276-84. PubMed ID: 18552871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: a positron emission tomography study with 11C McN 5652.
    Kent JM; Coplan JD; Lombardo I; Hwang DR; Huang Y; Mawlawi O; Van Heertum RL; Slifstein M; Abi-Dargham A; Gorman JM; Laruelle M
    Psychopharmacology (Berl); 2002 Dec; 164(4):341-8. PubMed ID: 12457263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors.
    Hirano K; Kimura R; Sugimoto Y; Yamada J; Uchida S; Kato Y; Hashimoto H; Yamada S
    Br J Pharmacol; 2005 Mar; 144(5):695-702. PubMed ID: 15678084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.